Sanofi

Sanofi logo
🇫🇷France
Ownership
Public
Employees
87.9K
Market Cap
$141.3B
Website
http://www.sanofi.com
Introduction

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

Phase 4
Completed
Conditions
First Posted Date
2005-12-07
Last Posted Date
2009-09-15
Lead Sponsor
Sanofi
Registration Number
NCT00263055
Locations
🇰🇷

Sanofi-aventis, Seoul, Korea, Republic of

🇹🇭

Sanofi-Aventis, Bangkok, Thailand

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

First Posted Date
2005-12-07
Last Posted Date
2016-05-20
Lead Sponsor
Sanofi
Target Recruit Count
18695
Registration Number
NCT00263042
Locations
🇬🇧

Sanofi-Aventis Administrative Office, Guildford, United Kingdom

🇦🇺

sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Phase 2
Terminated
Conditions
First Posted Date
2005-12-07
Last Posted Date
2008-03-20
Lead Sponsor
Sanofi
Target Recruit Count
50
Registration Number
NCT00263016
Locations
🇭🇰

Sanofi-aventis, Hong Kong, Hong Kong

Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension

Phase 3
Completed
Conditions
First Posted Date
2005-12-07
Last Posted Date
2007-12-07
Lead Sponsor
Sanofi
Target Recruit Count
40
Registration Number
NCT00263003
Locations
🇨🇳

Sanofi-Aventis, Taipei, Taiwan

Docetaxel in Head and Neck Cancer

First Posted Date
2005-12-05
Last Posted Date
2012-05-11
Lead Sponsor
Sanofi
Target Recruit Count
439
Registration Number
NCT00261703
Locations
🇪🇸

Sanofi-Aventis, Barcelona, Spain

Telithromycin in Respiratory Tract Infections

Phase 4
Completed
Conditions
First Posted Date
2005-12-02
Last Posted Date
2009-09-25
Lead Sponsor
Sanofi
Registration Number
NCT00261105

GEMOX: Oxaliplatin in Pancreatic Cancer

Phase 2
Completed
Conditions
First Posted Date
2005-12-02
Last Posted Date
2008-04-15
Lead Sponsor
Sanofi
Target Recruit Count
48
Registration Number
NCT00261092
Locations
🇰🇷

Sanofi-Aventis, Seoul, Korea, Republic of

Immunogenicity and Safety of Pentaxim™ in an Indian Population

First Posted Date
2005-11-29
Last Posted Date
2012-04-16
Lead Sponsor
Sanofi
Target Recruit Count
226
Registration Number
NCT00259337

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

First Posted Date
2005-11-29
Last Posted Date
2010-02-15
Lead Sponsor
Sanofi
Target Recruit Count
629
Registration Number
NCT00259376
Locations
🇦🇺

sanofi-aventis Australia administrative office, Macquarie Park, Australia

🇿🇦

Sanofi-Aventis Administrative Office, Midrand, South Africa

EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)

First Posted Date
2005-11-29
Last Posted Date
2010-02-09
Lead Sponsor
Sanofi
Target Recruit Count
615
Registration Number
NCT00259428
Locations
🇭🇺

Sanofi- Aventis Administrative Office, Budapest, Hungary

🇬🇧

Sanofi-Aventis Administrative Office, Guildford, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath